-+ 0.00%
-+ 0.00%
-+ 0.00%

Wells Fargo Maintains Overweight on Rhythm Pharmaceuticals, Raises Price Target to $155

Benzinga·06/15/2026 13:04:59
Listen to the news
Wells Fargo analyst Derek Archila maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Overweight and raises the price target from $144 to $155.